We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Schering-Plough will pay $345 million to resolve criminal and civil charges for illegal pricing activities in an agreement reached with the Justice Department and the U.S. Attorney's Office for the Eastern District of Pennsylvania.
According to a new study that apparently rebuts critics who allege mail pharmacies steer patients to higher priced brand products, the discrepancy in generic drug dispensing rates between retail and mail-order pharmacies disappears when therapeutic classes are accounted for.
Pfizer plans to file lawsuits against several unlicensed internet-based pharmacies, as well as initiate legal proceedings to seize 24 internet domain names using the company’s Viagra trademark, to block sales of counterfeit versions of its erectile dysfunction (ED) drug, the company announced last week.
In what is sure to get the attention of many drugmakers, GlaxoSmithKline’s (GSK’s) top executive said that moving human clinical trials to low-cost countries could save the company more than $200 million annually in R&D costs.
OTC drugmaker Perrigo is negotiating a settlement with the FTC to end its investigation into the firm’s agreement with a rival generic drugmaker that gave Perrigo a jump on marketing a children’s ibuprofen suspension product.
A senior scholar at the libertarian Cato Institute recommends that the U.S. repeal its ban on the importation of Rx drugs and allow pharmaceutical companies and foreign countries to work out on their own what the latter will pay for U.S. patented medicines.
HHS Secretary Tommy Thompson will not overrule the National Institutes of Health’s (NIH’s) decision to deny a request by an advocacy group to break patents on Abbott Laboratories’ AIDS drug Norvir and authorize generic competition, an HHS official said yesterday.
St. Jude Medical last week split its Daig division into separate cardiology and atrial fibrillation AF units, reflecting the firm’s desire to explore the growth potential in its developing electrophysiology and catheter product lines.
Despite a $78 million pretax charge related to the recent recall of its Taxus drug-eluting stent, Boston Scientific last week posted record second-quarter earnings.